triazole-aryl-adamantane-Cpd32
IC50 AChE= 0.086 microM), and significant Abeta aggregation inhibition (20 microM). N-methyl-d-aspartate (NMDA) receptor (GluN1-1b/GluN2B subunit combination) antagonistic activity
General
Type : Multitarget, NMDA-Ligand, Adamantyl, Triazol
Chemical_Nomenclature : N-((1-(4-bromobenzyl)-1H-1,2,3-triazol-4-yl)methyl)adamantan-1-amine
Canonical SMILES : C1C3CC2(CC1CC(C2)C3)NCC4=C[N](N=N4)CC5=CC=C(C=C5)Br
InChI : InChI=1S\/C20H25BrN4\/c21-18-3-1-14(2-4-18)12-25-13-19(23-24-25)11-22-20-8-15-5-16(9-20)7-17(6-15)10-20\/h1-4,13,15-17,22H,5-12H2
InChIKey : SUGGZYOMXAQALQ-UHFFFAOYSA-N
Other name(s) :
Target
Families : triazole-aryl-adamantane-Cpd32 ligand of proteins in family
ACHE
References (1)
| Title : Discovery of triazole-bridged aryl adamantane analogs as an intriguing class of multifunctional agents for treatment of Alzheimer's disease - Gutti_2023_Eur.J.Med.Chem_259_115670 |
| Author(s) : Gutti G , Leifeld J , Kakarla R , Bajad NG , Ganeshpurkar A , Kumar A , Krishnamurthy S , Klein-Schmidt C , Tapken D , Hollmann M , Singh SK |
| Ref : Eur Journal of Medicinal Chemistry , 259 :115670 , 2023 |
| PubMedID: 37515920 |